D
Immunome, Inc.
IMNM
$5.56
-$0.32-5.44%
D
Sell
3/28/2024Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 3/28/2024 due to a large increase in the total return index, solvency index and valuation index. Debt to equity declined from 0.04 to 0.
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 3/28/2024 due to a large increase in the total return index, solvency index and valuation index. Debt to equity declined from 0.04 to 0.
E
Sell
2/7/2024Downgrade
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 2/7/2024 due to a decline in the valuation index and growth index.
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 2/7/2024 due to a decline in the valuation index and growth index.
D
Sell
12/1/2023Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 12/1/2023 due to an increase in the total return index and volatility index.
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 12/1/2023 due to an increase in the total return index and volatility index.
E
Sell
8/14/2023Downgrade
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 8/14/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.79 to 1.46.
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 8/14/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.79 to 1.46.
D
Sell
6/29/2023Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 6/29/2023 due to an increase in the volatility index and total return index.
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 6/29/2023 due to an increase in the volatility index and total return index.
E
Sell
6/14/2023Downgrade
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 6/14/2023 due to a decline in the volatility index and total return index.
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 6/14/2023 due to a decline in the volatility index and total return index.
D
Sell
5/30/2023Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 5/30/2023 due to an increase in the total return index and valuation index.
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 5/30/2023 due to an increase in the total return index and valuation index.
E
Sell
5/12/2023Downgrade
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 5/12/2023 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 2.77 to 1.79.
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 5/12/2023 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 2.77 to 1.79.
D
Sell
11/22/2022Downgrade
Immunome, Inc. (IMNM) was downgraded to D- from D on 11/22/2022 due to a substantial decline in the growth index and solvency index. The quick ratio declined from 4.05 to 3.71, and earnings per share declined from -$0.74 to -$0.7549.
Immunome, Inc. (IMNM) was downgraded to D- from D on 11/22/2022 due to a substantial decline in the growth index and solvency index. The quick ratio declined from 4.05 to 3.71, and earnings per share declined from -$0.74 to -$0.7549.
D
Sell
8/8/2022Upgraded
Immunome, Inc. (IMNM) was upgraded to D from D- on 8/8/2022 due to a large increase in the growth index. EBIT increased 23.41% from -$11.65M to -$8.93M, and earnings per share increased from -$0.9612 to -$0.74.
Immunome, Inc. (IMNM) was upgraded to D from D- on 8/8/2022 due to a large increase in the growth index. EBIT increased 23.41% from -$11.65M to -$8.93M, and earnings per share increased from -$0.9612 to -$0.74.
D
Sell
5/23/2022Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 5/23/2022 due to an increase in the solvency index, volatility index and valuation index.
Immunome, Inc. (IMNM) was upgraded to D- from E+ on 5/23/2022 due to an increase in the solvency index, volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index and total return index.
Immunome, Inc. (IMNM) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
3/29/2022Downgrade
Immunome, Inc. (IMNM) was downgraded to D- from D on 3/29/2022 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 7.78 to 5.06.
Immunome, Inc. (IMNM) was downgraded to D- from D on 3/29/2022 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 7.78 to 5.06.
D
Sell
11/3/2021Upgraded
Immunome, Inc. (IMNM) was upgraded to D from D- on 11/3/2021 due to a noticeable increase in the total return index, valuation index and growth index.
Immunome, Inc. (IMNM) was upgraded to D from D- on 11/3/2021 due to a noticeable increase in the total return index, valuation index and growth index.
D
Sell
7/1/2021Upgraded
Immunome, Inc. (IMNM) was upgraded to D- from E on 7/1/2021 due to a noticeable increase in the efficiency index, growth index and valuation index. Operating cash flow increased 41.69% from -$6.06M to -$3.54M, earnings per share increased from -$0.3997 to -$0.3663, and EBIT increased 4.32% from -$4.07M to -$3.9M.
Immunome, Inc. (IMNM) was upgraded to D- from E on 7/1/2021 due to a noticeable increase in the efficiency index, growth index and valuation index. Operating cash flow increased 41.69% from -$6.06M to -$3.54M, earnings per share increased from -$0.3997 to -$0.3663, and EBIT increased 4.32% from -$4.07M to -$3.9M.
E
Sell
4/12/2021Upgraded
Immunome, Inc. (IMNM) was upgraded to E from E- on 4/12/2021 due to an increase in the total return index and valuation index.
Immunome, Inc. (IMNM) was upgraded to E from E- on 4/12/2021 due to an increase in the total return index and valuation index.
E
Sell
3/26/2021Downgrade
Immunome, Inc. (IMNM) was downgraded to E- from E on 3/26/2021 due to a decline in the valuation index and efficiency index.
Immunome, Inc. (IMNM) was downgraded to E- from E on 3/26/2021 due to a decline in the valuation index and efficiency index.
E
Sell
1/11/2021Upgraded
Immunome, Inc. (IMNM) was upgraded to E from E- on 1/11/2021 due to an increase in the volatility index and total return index.
Immunome, Inc. (IMNM) was upgraded to E from E- on 1/11/2021 due to an increase in the volatility index and total return index.
E
Sell
12/28/2020None
Immunome, Inc. (IMNM) was downgraded to E- from U on 12/28/2020.
Immunome, Inc. (IMNM) was downgraded to E- from U on 12/28/2020.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
